3-(4-溴苯磺酰氨基)-苯甲酸 | 59256-24-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(4-溴苯磺酰氨基)-苯甲酸
• 英文名称: 3-(4-bromophenylsulfonamido)benzoic acid
• 英文别名: 3-(4-Bromo-benzenesulfonylamino)-benzoic acid；3-[(4-bromophenyl)sulfonylamino]benzoic acid
• CAS: 59256-24-5
• 化学式: C₁₃H₁₀BrNO₄S
• mdl: MFCD00593145
• 分子量: 356.197
• InChiKey: BUTBMLDLLOBSFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2935009090

反应信息

• 作为反应物：
  描述：

  3-(4-溴苯磺酰氨基)-苯甲酸 在 吡啶 、 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 3-(4-bromophenylsulfonamido)-N-(2,4-dichlorophenyl)benzamide
  参考文献：
  名称：

  Anthranilic amide and imidazobenzothiadiazole compounds disruptMycobacterium tuberculosismembrane potential

  摘要：

  化合物1和2破坏结核分枝杆菌膜电位，并在pH 4.5缓冲液中对非复制的结核分枝杆菌表现出杀菌活性。

  DOI：

  10.1039/c9md00088g
• 作为产物：
  描述：

  间氨基苯甲酸 、 4-溴苯磺酰氯 在 sodium carbonate 作用下， 以 水 为溶剂， 以54%的产率得到3-(4-溴苯磺酰氨基)-苯甲酸
  参考文献：
  名称：

  Anthranilic amide and imidazobenzothiadiazole compounds disruptMycobacterium tuberculosismembrane potential

  摘要：

  化合物1和2破坏结核分枝杆菌膜电位，并在pH 4.5缓冲液中对非复制的结核分枝杆菌表现出杀菌活性。

  DOI：

  10.1039/c9md00088g

文献信息

• Hydroxamic acid with benzenesulfonamide: An effective scaffold for the development of broad-spectrum metallo-β-lactamase inhibitors
  作者：Jia-Qi Li、Cheng Chen、Min Yao、Le-Yun Sun、Han Gao、Jiazhu Chigan、Ke-Wu Yang

  DOI：10.1016/j.bioorg.2020.104436

  日期：2020.12

  Given that β-lactam antibiotic resistance mediated by metallo-β-lactamases (MβLs) seriously threatens human health, we designed and synthesized nineteen hydroxamic acids with benzenesulfonamide, which exhibited broad-spectrum inhibition against four tested MβLs ImiS, L1, VIM-2 and IMP-1 (except 6, 13 and 18 on IMP-1, and 18 on VIM-2), with an IC50 value in the range of 0.6–9.4, 1.3–27.4, 5.4–43.7 and

  鉴于金属β-内酰胺酶（MβLs）介导的β-内酰胺抗生素耐药性严重威胁人类健康，我们与苯磺酰胺一起设计并合成了19种异羟肟酸，对四种测试的MβLs ImiS、L1、VIM-2和IMP-1（IMP-1 上的6、13和18以及 VIM-2 上的 18除外），IC 50值分别在 0.6–9.4、1.3–27.4、5.4–43.7 和 5.2–49.7 µM 范围内，并恢复了头孢唑啉和美罗培南的抗菌活性，导致抗生素的 MIC 降低了 2-32 倍。化合物17对 L1 显示出可逆的竞争性抑制作用， K i值为 2.5 µM，并显着降低被表达 L1 的大肠杆菌感染的小鼠脾脏和肝脏中的细菌负荷。对接研究表明17通过磺酰胺基团的氧原子与VIM-2和CphA的Zn(II)紧密结合，但通过异羟肟酸基团的氧原子与L1的Zn(II)配位。这些研究表明，异羟肟酸与苯磺酰胺是开发 MβL 抑制剂的有效支架。
• [EN] ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ARYL-PHÉNYL-SULFONAMINO-PHÉNYLÈNE ET LEURS UTILISATIONS
  申请人：PIMCO 2664 LTD

  公开号：WO2010032010A1

  公开（公告）日：2010-03-25

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as "APSAP compounds"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.

  本发明通常涉及治疗化合物领域，更具体地涉及以下式(I)的某些芳基苯磺酰胺基苯基化合物（以下统称为“APSAP化合物”）。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体内外的使用，例如用于治疗炎症和/或关节破坏和/或骨质流失；过度和/或不适当和/或持续激活免疫系统的疾病；炎症性和自身免疫性疾病，例如类风湿关节炎、牛皮癣、银屑病性关节炎、慢性阻塞性肺病（COPD）、动脉粥样硬化、炎症性肠病、强直性脊柱炎等；与骨质流失相关的疾病，例如类风湿性关节炎中与过度破骨细胞活性相关的骨质流失、骨质疏松症、癌症相关骨病、帕吉特病等；以及癌症，如血液系统恶性肿瘤、实体肿瘤等。
• Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use
  申请人：Greig Iain Robert

  公开号：US20110190302A1

  公开（公告）日：2011-08-04

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.

  本发明涉及治疗化合物领域，更具体地涉及以下公式（I）的某些芳基-苯基-磺酰胺基-苯基化合物（以下统称为“APSAP化合物”）。本发明还涉及包含这些化合物的制药组合物，以及这些化合物和组合物的使用，无论是在体外还是体内，用于治疗炎症和/或关节破坏和/或骨质流失；治疗由免疫系统过度和/或不适当和/或持续激活引起的疾病；治疗炎症和自身免疫性疾病，例如类风湿性关节炎、牛皮癣、银屑病性关节炎、慢性阻塞性肺疾病（COPD）、动脉粥样硬化、炎性肠病、强直性脊柱炎等；治疗与骨质流失有关的疾病，例如类风湿关节炎中过度破骨细胞活动引起的骨质流失、骨质疏松症、癌症相关骨病、帕吉特病等；以及治疗癌症，例如血液系统恶性肿瘤、实体瘤等。
• Aryl-phenyl-sulfonamide-phenylene compounds and their use
  申请人：PIMCO 2664 Limited

  公开号：US08207167B2

  公开（公告）日：2012-06-26

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumor, etc.

  本发明涉及治疗化合物领域，更具体地涉及以下公式（I）的某些芳基-苯基-磺酰胺基-苯基化合物（统称为“APSAP化合物”）。本发明还涉及包含这种化合物的制药组合物，以及这种化合物和组合物的使用，无论是体外还是体内，用于治疗炎症和/或关节破坏和/或骨质流失等疾病；过度和/或不适当和/或长时间激活免疫系统介导的疾病；炎症性和自身免疫性疾病，例如类风湿性关节炎、银屑病、银屑病性关节炎、慢性阻塞性肺疾病（COPD）、动脉硬化、炎症性肠病、强直性脊柱炎等；与骨质流失有关的疾病，例如类风湿性关节炎中过度破骨细胞活性、骨质疏松症、与癌症相关的骨病、帕吉特病等；以及癌症，例如血液系统恶性肿瘤、实体肿瘤等。
• Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents
  申请人：Greig Iain Robert

  公开号：US20100286266A1

  公开（公告）日：2010-11-11

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as ‘BPSAAA compounds’), as described herein, and including, for example, biphenyl-4-sulfonic acid (hydroxyalkyl-phenyl)-amides and related compounds. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment and/or prevention, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of, inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis, osteoporosis, cancer associated bone disease, Paget's disease and the like.

  本发明涉及治疗化合物领域，更具体地涉及某些芳基磺酰胺和相关化合物（统称为“BPSAAA化合物”），如本文所述，包括例如联苯基-4-磺酸（羟基烷基-苯基）-酰胺和相关化合物。本发明还涉及包含这些化合物的制药组合物，以及这些化合物和组合物在体内外治疗和/或预防炎症、关节破坏和/或骨质流失等方面的使用，包括过度和/或不适当和/或持续激活免疫系统介导的疾病，炎症和自身免疫性疾病，例如类风湿性关节炎、银屑病、银屑病性关节炎、慢性阻塞性肺疾病（COPD）、动脉粥样硬化、炎症性肠病、强直性脊柱炎等，以及与骨质流失相关的疾病，例如类风湿性关节炎中过度成骨破骨细胞激活、骨质疏松症、癌症相关骨病、帕吉特病等。